論文 - 詳細
| RRC ID | 65465 |
|---|---|
| 著者 | Ma C, Horlad H, Pan C, Yano H, Ohnishi K, Fujiwara Y, Matsuoka M, Lee A, Niidome T, Yamanaka R, Takeya M, Komohara Y. |
| タイトル | Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. |
| ジャーナル | J Clin Exp Hematop |
| Abstract |
Recent studies have indicated the significance of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domain-containing molecule-3 for anti-tumor immune responses. We previously investigated PD-1 ligand 1/2 (PD-L1/2) expression in lymphoma cell lines, and found that PD-L1/2 is expressed on the adult T-cell leukemia/lymphoma (ATL-T) and B-cell lymphoma (SLVL) cell lines. In the present study, we investigated whether the Stat3 inhibitor WP1066 abrogated PD-L1/2 expression in lymphoma cell lines. Incubation with WP1066 inhibited lymphoma cell growth and induced cell apoptosis. PD-L1/2 expression in the ATL-T, SLVL, and human brain malignant lymphoma (HKBML) cell lines was significantly abrogated by WP1066 treatment. These data indicated that a Stat3 inhibitor abrogated PD-L1/2 expression in lymphoma cells. Such an inhibitor is therefore considered to be useful for additional immunotherapy in patients with advanced lymphoma. |
| 巻・号 | 57(1) |
| ページ | 21-25 |
| 公開日 | 2017-7-5 |
| DOI | 10.3960/jslrt.17006 |
| PMID | 28496056 |
| PMC | PMC6144272 |
| MeSH | Apoptosis / drug effects Apoptosis / genetics B7-H1 Antigen / genetics* Caspase 3 / metabolism Cell Line, Tumor Cell Proliferation / drug effects Down-Regulation Gene Expression Regulation, Neoplastic / drug effects* Humans Lymphoma / genetics* Lymphoma / metabolism Pyridines / pharmacology STAT3 Transcription Factor / antagonists & inhibitors* Tyrphostins / pharmacology |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | News |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | HKBML(RCB0820) |